ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Here's What to Expect From CME Group's Next Earnings Report

CME Group Inc. (CME), headquartered in Chicago, Illinois, operates contract markets for the trading of futures and options on futures contracts. Valued at $95.6 billion by market cap, the company offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, and more. It facilitates trading on its trading floors, electronic platform, and through privately negotiated transactions that it clears. The leading derivatives marketplace is expected to announce its fiscal fourth-quarter earnings for 2025 before the market opens on Wednesday, Feb. 4. 

Ahead of the event, analysts expect CME to report a profit of $2.72 per share on a diluted basis, up 7.9% from $2.52 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports. 

 

For the full year, analysts expect CME to report EPS of $11.17, up 8.9% from $10.26 in fiscal 2024. Its EPS is expected to rise 4% year over year to $11.62 in fiscal 2026. 

www.barchart.com

CME stock has underperformed the S&P 500 Index’s ($SPX19.3% gains over the past 52 weeks, with shares up 17% during this period. However, it outperformed the Financial Select Sector SPDR Fund’s (XLF13.8% gains over the same time frame.

www.barchart.com

On Oct. 22, 2025, CME shares closed down marginally after reporting its Q3 results. Its adjusted EPS of $2.68 topped Wall Street expectations of $2.63. The company’s revenue was $1.54 billion, topping Wall Street forecasts of $1.53 billion.

Analysts’ consensus opinion on CME stock is moderately bullish, with a “Moderate Buy” rating overall. Out of 17 analysts covering the stock, five advise a “Strong Buy” rating, two suggest a “Moderate Buy,” seven give a “Hold,” one recommends a “Moderate Sell,” and two advocate a “Strong Sell.” CME’s average analyst price target is $292.33, indicating a potential upside of 8.9% from the current levels. 


On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

 

More news from Barchart

Recent Quotes

View More
Symbol Price Change (%)
AMZN  207.67
-1.86 (-0.89%)
AAPL  250.12
-5.64 (-2.21%)
AMD  193.39
-4.35 (-2.20%)
BAC  46.72
-0.41 (-0.87%)
GOOG  301.46
-1.75 (-0.58%)
META  613.71
-24.47 (-3.83%)
MSFT  395.55
-6.31 (-1.57%)
NVDA  180.25
-2.89 (-1.58%)
ORCL  155.11
-4.05 (-2.54%)
TSLA  391.20
-3.81 (-0.96%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.